Clovis looks for new drugs after Rubraca success
June 20, 2017US biotech looks to bolster pipeline.
X
Clovis looks for new drugs after Rubraca success
https://pharmaphorum.com/news/clovis-looks-new-drugs-rubraca-success/
ovarian cancer
AZ highlights data from next-gen oncology drugs at ASCO
May 26, 2017Tesara and Takeda among other companies to publish data.
Doubts over AbbVie PARP inhibitor after double trial failure
April 20, 2017Veliparib fails in two phase 3 trials.
Tesaro’s niraparib approved in ovarian cancer
March 28, 2017Company nabs maintenance therapy use, but problems on breast cancer trial.
AZ’s Lynparza impresses with new ovarian cancer data
March 15, 2017UK firm lays down the gauntlet in the PARP inhibitor battle.
AZ looks to file Lynparza in breast cancer
February 17, 2017UK pharma also gets $130m payment from Valeant.
Early Clovis approval notches up competition in ovarian cancer
December 20, 2016Clovis’ Rubraca will compete against AstraZeneca rival.
Electrical patch device shows promise against ovarian cancer
December 15, 2016Novocure’s Optune device shown to be safe and tolerable in recurrent ovarian cancer.
Clovis takes stock as rival Tesaro shines
October 13, 2016Oncology firm could make acquisition if ovarian cancer drug approved.
1 2
